A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Conditions
Non Small Cell Lung Cancer Metastatic · ALK Gene Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, Italy
Azienda Ospedaliero-Universitaria Careggi Oncologia Medica, Florence, Italy
Azienda USL Toscana Nord Ovest Oncologia Medica, Ospedale Versilia, Lido di Camaiore, Italy
Contact: Study coordinator (Camerini Andrea) · andrea.camerini@uslnordovest.toscana.it · 05846057282Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino amadori", Meldola, Italy
Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
Contact: Study coordinator (Cortinovis Diego Luigi) · diegoluigi.cortinovis@irccs-sangerardo.it · 0392336040IOV Istituto Oncologico Veneto IRCCS, Padova, Italy
Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
Azienda Ospedaliera di Perugia, Perugia, Italy
Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Udine, Italy
Contact: Study coordinator (Giacomo Pellizzari) · giacomo.pelizzari@asufc.sanita.fvg.it · 0432552754